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BACKGROUND: Recently, transcriptional gene silencing induced by small interfering RNA (siRNA) was found in mammalian and human
cells. However, previous studies focused on endogenous genes.
METHODS: In this study, we designed siRNA targeting the promoter of human papillomavirus 16 E6/E7 and transfected it into the
cervical cancer cell line, SiHa. E6 and E7 mRNA and protein expression were detected in cells treated by promoter-targeting siRNA.
Futhermore, cellular growth, proliferation, apoptosis and senescence were detected. Thereafter, we investigated promoter DNA
methylation and histone methylation status in cells treated with promoter-targeting siRNA.
RESULTS: We found that E6/E7 mRNA and protein were simultaneously reduced, cell growth and proliferation were inhibited and cell
death, especially senescence, was remarkably increased. Meanwhile, we also found a significantly increasing histone H3-Lys9
methylation on the promoter when E6/E7 gene expression was inhibited.
INTERPRETATION: Our findings suggest that promoter-targeting siRNA effectively and simultaneously knocks down both extraneous
HPV 16 E6 and E7 at the transcriptional level, and consequently inhibits proliferation and induces death in HPV 16-infected cells.
This transcriptional repression is probably induced by histone modification rather than by alteration of DNA methylation.
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BACKGROUND
Small interfering RNA (siRNA) has been widely used to degrade
homologous mRNA at the post-transcriptional level. Recent
studies found that siRNA also targeted DNA and induced
transcriptional gene silencing (TGS). Initially, siRNA-mediated
TGS was observed in plants through the use of inverted repeat
transgenes to generate siRNAs homologous to the target promo-
ter (Mette et al, 2000). This kind of strategy has been demonstra-
ted to be useful for transcriptionally downregulating genes in a
variety of plants (Jones et al, 2001; Sijen et al, 2001). Recently,
transcriptional gene silencing induced by siRNA was also found in
mammalian cells (Morris et al, 2004; Ting et al, 2005). It was
reported that a siRNA, which was designed homologous to an
elongation factor 1 alpha (EF1A) promoter sequence and
transfected with an FIV vector, induced downstream gene silencing
at the transcriptional level in human 293FT cells (Morris et al,
2004). In addition, a synthetic siRNA targeted exclusively to the
CDH1 promoter could effectively induce transcriptional repression
with chromatin changes characteristic of inactive promoters.
Those results indicate that siRNA-induced TGS offers an
additional way of silencing genes, other than posttranscriptional
gene silencing (PTGS). However, most of the previous studies
focused on endogenous genes, especially on some inactivation
mechanism of tumour-suppressor genes. It has not been known
till date whether a promoter-targeting siRNA could induce gene
silencing of an extraneous viral gene such as human papilloma-
virus (HPV).
Human papillomavirus is a common type of DNA virus that
infects humans. Of them, high-risk HPV is associated with the
occurrence of cervical carcinoma. In a worldwide analysis, the
prevalence of high-risk HPV in cervical cancer was 99.7%, and
persistent infection of HPV is recognised to be a necessary cause of
cervical carcinoma (Walboomers et al, 1999). In addition, high-
risk HPV is also found to be a pathogenic factor associated with
other cancers, such as vulva, vaginal, rectal and oral cancer (Miller
and Johnstone, 2001; Daling et al, 2004). Among all the HPV
genotypes, HPV 16 is the most prevalent, with a proportion of
65.2% of all genotypes in cervical cancer (Hong et al, 2008).
Various publications have demonstrated that continuous expres-
sion of both viral oncogenes, E6 and E7, is necessary during HPV
induction of malignant transformation and maintenance in
cervical epithelial cells (Goodwin and DiMaio, 2000; Munger
et al, 2004). Considering the crucial effect of E6/E7 in carcinogen-
esis, almost all studies focus on the induction of PTGS of E6 and/or
E7 expression (Jiang and Milner, 2002; Yoshinouchi et al, 2003).
It has been found that the expression of HPV 16 E6 and E7 is
controlled by a common promoter (P97) that is located
immediately upstream of the E6 gene (Smotkin and Wettstein,
1986). The promoter region contains several binding sites for
cellular transcription factors such as TFIID (Dostatni et al, 1991),
Sp1 and E2 (Tan et al, 1992), all of which modulate its function.
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the function of the promoter. For example, methylation within the
binding sites of transcription factors such as Sp1 might block
binding indirectly, either by changing the conformation of
chromatin or by interacting with methyl-CpG-specific repressor
proteins (Zhu et al, 2003). It is generally believed that the strength
of transcription from P97 will determine the concentration of the
oncoprotein E6/E7 (Stunkel et al, 2000). The common promoter of
E6/E7 offers a possibility to knock down the E6/E7 gene
simultaneously by means of siRNA-mediated TGS.
In this study, we designed siRNA targeting the promoter
of E6/E7 to explore whether it is likely to knock down both genes
simultaneously at the transcriptional level, and consequently
inhibit proliferation and induce death in HPV-positive cells.
After E6/E7 silencing was observed, we further investigated its
association with promoter DNA methylation and histone methyla-
tion to explore a novel mechanism of HPV E6/E7 silencing by
siRNA.
METHODS
Design and synthesis of promoter-targeting siRNA
The criteria described by Sohail et al (2003) and the computer
programme available at http://www.promega.com/siRNADesigner/
program/ were used to design siRNA. The T7 RiboMAX Express
RNAi System Kit (Promega, Madison, WI, USA) was used to
synthesise siRNA. The sequence of siRNA was designed to
complement the common promoter P97 of E6/E7 in HPV 16
(NC_001526). The promoter-targeting siRNA contained 21 nucleo-
tides (nt) of the target sequence, homologous to the promoter of
E6/E7 (position in gene sequence 32–52 nt). The promoter-
targeting siRNA sense strand was GUAACCGAAAUCGGUUGA
ACC and the promoter-targeting siRNA antisense strand was
CAUUGGCUUUAGCCAACUUGG. A scrambled siRNA was used as
negative control. The sequence was submitted to a BLAST search
against the human genome sequence to ensure that no gene of the
human genome was targeted.
Cell culture and siRNA transfection
A human cervical carcinoma cell line, SiHa, was used in this study.
In SiHa cells, HPV16 DNA is integrated into the cellular genome.
Moreover, DNA in this region is unmethylated.
Three groups were included in the experiments: the promoter-
targeting siRNA transfected with liposome was considered as the
experiment group; scrambled siRNA transfected with liposome
was considered as negative control and liposome without siRNA as
blank control.
SiHa cells were transferred to 12-well plates for most experi-
ments. However, 6-well and 96-well plates, and 60-mm dishes were
used in apoptosis, proliferation and histone detection experiment
according to the introduction of the kit. The dose of siRNA used
was altered correspondingly.
SiHa cells were transferred to the plate and cultured for
24h. An appropriate cell density of 30–40% was chosen before
siRNA transfection. siRNA was transferred with the liposome of
CodeBreaker siRNA Transfection Reagent (Promega, WI, USA)
according to the manufacturer’s instructions. After 24h of
incubation, the cells were washed once, and after 48h, they were
collected.
Before the experiment, we used siRNAs in SiHa with different
concentrations (20, 40, 60 and 80mM). Finally, we selected 40mM
siRNA as the experiment concentration, according to the growth
state of the negative control and the mRNA expression level of
E6 and E7 in SiHa transferred with promoter-targeting siRNA
(data not shown). Data were collected from three trials of the same
experiment.
Detection of E6 and E7 expression
E6 E7 mRNA was detected by RT–PCR. The amplified regions
were both in the exons of E6 (position in gene sequence 421–540
nt) and E7 genes (642–774 nt). Total RNA was obtained from
cells with Trizol and chloroform. After RNA identification and
DNA digestion, mRNA was reversely transcripted to single-
stranded cDNA with oligodT (18). cDNA samples were diluted
and subjected to PCR amplification with forward and reverse
primers specific to HPV16 E6, E7 and b-actin (seen in Table 1).
PCR analyses of E6 and E7 cDNA fragments were performed
under the following conditions: denaturation was at 941C for
5min, followed by 24–26 PCR cycles to ensure amplification in the
linear stage (denaturation at 941C for 30s, primer annealing at
581C for 1min, primer extension at 681C for 2min). b-Actin
cDNA was detected under almost the same conditions, with three
cycles fewer. For every PCR assay, a negative control and a posi-
tive control were used to avoid possible false positives and
false negatives. Amplified products were separated on 2%
agarose gels. Intensities of E6 and E7 bands were quantified using
the Image Gauge software and normalised to those of b-actin
bands.
Because E6 proteins were unsuccessfully detected by western
blotting with several commercial anti-E6 antibodies (Butz et al,
2003), E6 and E7 proteins were only detected by immunocyto-
chemistry. Cells were seeded on slides in 12-well plates. After
siRNA was treated for 48h, 4% paraformaldehyde was used to fix
cells on the slides and 0.1% Triton X-100 was used to break the
nuclear member. Subsequently, slides were incubated with
monoclonal antibodies to E6 (Calbiochem, Darmstadt, Germany)
diluted 1:50 and to E7 (Santa Cruz, Santa Cruz, CA, USA) diluted
1:75 separately in PBS for 1h, and then incubated with Dako
Envision peroxidase for 1h. Thereafter, 3,30-diaminobenzidine
tetrahydrochloride was added for visualisation and Mayer’s
haematoxylin was used to counterstaining. Positive cells were
indicated by the presence of a distinct brown stain in the nucleus
or cytoplasm of cells. Treatment of blank control was performed
by replacing E6 or E7 antibodies with normal rabbit serum.
Treatment of negative control was performed using C33A (a
cervical cancer cell without HPV infection). The immunoreaction
of E6 and E7 protein expression was semi-quantitatively scored in
the same manner as that in previous study (Innocenzi et al, 2003).
Table 1 The primer sequences for PCRs
Primer Sequence
E6F 50-TCAAAAGCCACTGTGTCCTG-30
E6R 50-CGTGTTCTTGATGATCTGCA-30
E7F 50-ATTAAATGACAGCTCAGAGGA-30
E7R 50-GCTTTGTACGCACAACCGAAGC-30
b-ActinF 50-TTCCAGCCTTCCTTCCTGG-30
b-ActinR 50-TTGCGCTCAGGAGGAGCAAT-30
msp7708F 50-TTTTGGTTTGTTTTAATTAA-30
msp161R 50-ACAACTCTATACATAACTATAATA-30
msp115R 50-ATCCTAAAACATTACAATTCTCTTTTAATA-30
msp53mR 50-CGATTCAACCGATTTCGATTACGCCCTT-30
msp53nmR 50-CAATTCAACCAATTTCAATTACACCCTT-30
Pyro-msp11F 50-TTTATGTATAAAATTAAGGG-30
F14 50-ATGTATAAAACTAAGGGCGTAA-30
R113 50-CCTGAAACATTGCAGTTCTC-30
GAPDH-F 50-TACTAGCGGTTTTACGGGCG-30
GAPDH-R 50-TCGAACAGGAGGAGCAGAGAGCGA-30
Abbreviations: GAPDH¼glyceraldehyde-3-phosphate dehydrogenase; PCR¼poly-
merase chain reaction.
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Cellular growth, including density and morphology of cells,
was observed using a phase-contrast microscope. On the basis of
the measurement of BrdU incorporation during DNA synthesis,
cellular proliferation was detected by colorimetric immunoassay
using a Cell Proliferation ELISA, BrdU (colorimetric) kit (Roche)
according to the manufacturer’s instructions. The reaction product
was quantified by measuring absorbance at the respective
wavelength using a scanning spectrophotometer. The absorbance
values were directly correlated to the amount of DNA synthesis
and, thereby, to the number of proliferating cells.
To assess the rate of cell apoptosis, annexin-V binding and
propidium iodide permeability were examined by flow cytometry.
Apoptosis cells were quantified by annexin-V–FITC and propi-
dium iodide double staining using an Annexin-V/FITC kit (Bender
MedSystems, Burlingame, CA, USA), according to the manufac-
turer’s instructions. The log of annexin-V–FITC and propidium
iodide fluorescence was displayed on the x- and y-axis of the
cytogram, respectively. Annexin-V-positive cells plotted in the
lower and upper right quadrants were evaluated as dead cells.
Senescence-associated b-galactosidase assay (SAb-gal) was used
to detect cell senescence using a cell senescence testing kit
(Genmed Scientifics, Arlington, VA, USA). After treatment with
siRNA for 48h, SiHa cells were fixed and incubated overnight with
an SAb-gal staining solution at 371C until a green precipitate
appeared. The positive cells were counted by light microscopy at
 200 magnification and five random fields were also counted.
Detection of DNA methylation
Different methods, including Sanger DNA sequencing, methyla-
tion-specific PCR and pyrosequencing, were used to detect DNA
methylation in the promoter of E6 and E7. All these methods
were based on PCR and the template was treated with sodium
bisulphite. Bisulphite treatment of DNA converted epigenetic
information into a genetic polymorphism. Genomic DNA was
treated with sodium bisulphite as before (Grunau et al, 2001) to
transfer unmethylated C to T, and to maintain methylated C as C.
All primer sequences are shown in Table 1.
First, Sanger DNA sequencing of PCR amplifier was performed.
Semi-nested PCR was used to acquire the amplifier. The outer
primers of PCR were msp7708F and msp161R (319bp), and the
inner primers were msp7708F and msp115R (273bp). If the CpG
sites in the promoter became methylated, two apices of C and T
would simultaneously show in the CpG position.
Thereafter, methylation-specific PCR (MSP) was used when
sequencing did not differentiate between the methylated and
unmethylated state. MSP distinguishes between unmethylated
and methylated alleles by using two sets of primers that amplify
either unmethylated or methylated sequences after bisulphite
treatment. In this study, we used a pre-amplified common PCR
product as the template of MSP for sensitivity of detection. The
outer PCR used common primers of msp7708F and msp161R, and
the inner PCR used a methylation primer and an unmethylation
primer. The methylation primers used in this study were
msp7708F and 53mR, and the unmethylation primers were
msp7708F and 53nmR.
Finally, a quantifiable method of pyrosequencing was used to
verify the result of MSP. Pyrosequencing is a good method for
analysing methylation status with simultaneous quantification
(Dupont et al, 2004; Wong et al, 2006). The accuracy of
pyrosequencing is not less than that of subcloning and sequencing.
The advantage of the method was to quantify the percentage of
C and T in the target CpG site. The method was also based on PCR.
The primers used in the PCR were approximately identical with
those for Sanger DNA sequencing, with only the reverse primer
115R biotinylated. The primer of pyrosequencing was pyro-
msp11F. The protocol was as usual (Rajeevan et al, 2006).
Detection of histone methylation
We detected trimethyl-histone H3-Lys9 (H3K9me3) by chromatin
immunoprecipitation (ChIP) assay and real-time PCR. We
processed SiHa cells in accordance with the Upstate ChIP assay kit
protocol (17-611, Upstate, Temecula, CA, USA), and used ChIPAb
þtrimethyl-histone H3 (Lys9) (17-625, Temecula, CA, USA,
Upstate) as the special antibody. We analysed the ChIP results
by real-time PCR using SYBR Premix Ex Taq (Takara, Dalian,
China) with a set of HPV 16 promoter-specific primers (F16 and R 113)
spanning the HPV 16 promoter (position in gene sequence 16-113nt).
We also performed PCR of GAPDH (GAPDH-F and GAPDH-R) on
the same sets of immunoprecipitated DNA fractions as controls.
Statistical analysis
Data were analysed with independent-samples t-test and the
Mann–Whitney test using SPSS version 11.5 for Windows. All
P-values less than 0.05 were considered statistically significant.
All reported P-values were bilateral.
RESULTS
Simultaneously reduced expression of the E6 and E7
oncogene by siRNA targeting the E6/E7 promoter
HPV 16 E6 and E7 mRNA expressions were determined by semi-
quantitative RT–PCR. In SiHa cells transfected by promoter-
targeting siRNA, the E6 mRNA expression was decreased by 45.2%
as compared with that in the negative control (P¼0.022), and
decreased by 49.7% as compared with that in the blank control
(P¼0.009). At the same time, E7 mRNA expression was
simultaneously decreased by 41.7 and 40.2%, respectively, as
compared with that in the negative control (P¼0.017) and blank
control (P¼0.022; Figure 1).
The expression of E6 and E7 protein in cells was determined
by immunocytochemistry. Semi-quantitative analysis showed
that E6 protein expression in SiHa cells treated with promoter-
targeting siRNA was decreased by 33.3 and 37.1%, respectively,
as compared with that in the negative control (P¼0.009)
and blank control (P¼0.002). Simultaneously, the E7 protein
1.5
1
0.5
0
Promoter-siRNA Negative control Blank control
E6
E7
Figure 1 The expression of HPV16 E6 and E7 mRNA in SiHa cells by
promoter–siRNA. E6 and E7 mRNA expression detected by RT–PCR.
The x-axes show different experiment groups (promoter siRNA, negative
control, blank control); y-axes show the E6/E7 level, which was normalised
to that of negative control. E6 and E7 mRNA expression was decreased by
45.2 and 41.7% separately as compared with the negative control.
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was decreased by 30.3 and 34.2%, respectively, as compared with
that in the negative control (P¼0.017) and blank control
(P¼0.004; Figure 2).
Reduced cellular growth and proliferation, increased
apoptosis and senescence in SiHa cells treated by
promoter-siRNA
To examine whether suppression of E6 and E7 affected cell growth,
cellular morphology, proliferation, apoptosis and senescence were
detected. At 48h after transfection, cell morphology was changed
in promoter-targeting siRNA-treated cells as compared with that in
the negative and blank control. Promoter-targeting siRNA-treated
cells showed slower growth, with some small vacuoles in the
cytoplasm of cells, but no morphological change was found in the
negative and blank control cells (Figure 3).
The cellular proliferation state was also detected by colorimetric
immunoassay with Cell Proliferation ELISA of BrdU. For cellular
proliferative rate, cells treated by promoter-targeting siRNA
showed a 22.2 and 29.8% decrease than the negative (P¼0.000)
and blank control (P¼0.000; Figure 4).
Apoptotic cells were quantified by annexin-V–FITC by flow
cytometry. Generally, the apoptotic rates were relatively low. The
apoptotic rate was 4.4±0.8, 1.7±1.0 and 1.6±0.6%, respectively,
for cell treated with promoter-targeting siRNA, the negative
control and blank control. However, the apoptotic cells in the
experiment group were also more than those in the negative
(P¼0.009) and blank control (P¼0.022; Figure 5A).
Senescence-associated b-galactosidase assay was used to detect
cell senescence. The senescence rate of cells treated by promoter-
targeting siRNA was 57.1±4.4%, which was significantly higher
than that of the negative control (35.8±3.1%, P¼0.000) and blank
control (32.8±4.0%, P¼0.000; Figure 5B).
No DNA methylation alteration but increased H3K9me3
in the promoter of HPV16 in SiHa cells treated by
promoter-siRNA
Although MSP analysis showed mixed methylation in promoter-
targeting siRNA-treated cells, the result could not be verified in
both Sanger DNA sequencing and pyrosequencing. Sanger
DNA sequencing showed a single peak of T in the sequence
map, indicating that no methylation was detected. Pyrosequening
showed that the frequency of T (represents the unmethylated G)
was 100% in all of the five CpG sites of the HPV16 promoter
(Figure 6A).
Chromatin immunoprecipitation assay and real-time PCR
showed that H3K9me3 adjacent to the promoter was significantly
increased in promoter-targeting siRNA-treated cells than in both
the controls (Figure 6B).
Interpretation
Previous studies demonstrated that the siRNA-targeting promoter
DNA can induce downstream gene silencing at the transcriptional
level in human and mammary cells. In this study, we found that
siRNA targeting the promoter of E6/E7 effectively and simulta-
neously inhibited the expression of both E6 and E7 in SiHa cells.
At the same time, our data confirmed that the activity of siRNA-
targeting promoter was at the transcriptional level. To our know-
ledge, it is the first report that a promoter-targeting siRNA induces
the silence of extrinsic viral genes of HPV. Our study showed that
siRNA-targeting promoter interferes with mRNA transcription,
reaching more than 40 and 30%, respectively decrease in E6/E7
mRNA and protein, respectively, suggesting that the siRNA-
targeting promoter of E6/E7 is able to effectively knock down
E6/E7 expression simultaneously.
A unique feature of HPV-associated cancer is that the main-
tenance of the malignant aspect and behaviour of cancer cells is
dependent on the expression of viral protein E6 and E7. In case the
E6/E7 expression is inhibited, the cellular malignant characteristics
would be abrogated. In our study, the moderate decreases in E6/E7
mRNA and protein expression also partially altered the malignant
characteristics. At the same time, cells treated by the siRNA-
targeting E6/E7 promoter represented a remarkably decreased
proliferation, as well as changed cellular growth morphology.
Furthermore, we found that cell death, including apoptosis and
senescence, was induced; it is to be especially noted that
senescence was remarkably increased when E6 and E7 expression
was inhibited at the transcriptional level. It is interesting that sen-
escence is a more common form than apoptosis in cell death
E6
E7
Promoter-siRNA Negative control Blank control
Figure 2 The expression of HPV16 E6 and E7 proteins in SiHa cells by promoter–siRNA. E6 and E7 protein expression detected by
immunocytochemistry (400 ). E6 protein (A–C) and E7 protein (D–F) were mainly located in the nucleus. If the protein is highly expressed, the nucleus
and plasma were stained brown. The percentage of cell stained was measured by image analysis from 10 random fields from each cell slide, and data were
pooled to determine the mean. It was shown that E6 and E7 proteins in SiHa treated with promoter–siRNA (A, D) were expressed lower than that of the
negative control (B, E) and blank control (C, F).
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gene silencing (Butz et al, 2003; Hall and Alexander, 2003; Horner
et al, 2004). E7 acts as a mitotic mutator and growth-stimulatory
factor that interferes with cellular senescence and proper
differentiation, whereas E6 counteracts the apoptotic response of
HPV-positive cells towards the abnormal growth stimulus exer-
ted by E7, ultimately resulting in deregulated growth of geneti-
cally unstable cells (Mantovani and Banks, 2001). Thus, when E6
alone is targeted, cells readily become apoptotic. However,
when both are inhibited, senescence is predominantly droven
and apoptosis is reduced. (Butz et al, 2003; Hall and Alexander,
2003).
Recent studies of mammalian cells indicate that siRNA-
mediated transcriptional gene silencing is likely to be affected by
multiple epigenetic factors, such as histone modification and
cytosine methylation. There are some data that a histone-
methylation-mediated heterochromatin pathway is essential for a
number of biological processes in mammalian systems, including
genomic stability and development (Grewal and Rice, 2004).
Methylation of histone H3-Lys9 is a common histone mark
generally associated with an inactively transcribed promoter. Ting
reported that the small double-stranded RNAs that targeted
exclusively to the CDH1 promoter could effectively induce
transcriptional repression with chromatin changes characteristic
of inactive promoters. They successfully detected dimethylation
of Lys9 of histone H3 (H3K9me2) only at the CDH1 promoter
in cells treated with dsCDH1-1 (Ting et al, 2005). In this study,
we detected H3K9me3 after treatment of promoter-targeting
siRNA. H3K9me3 was detected adjacent to the target region and
we also found significant increase in its levels promoter-targeting
siRNA-treated cells, which suggests that histone modification
participates in gene silencing of HR-HPV E6 and E7 at the
transcriptional level. Several publications also demonstrated the
consistency between transcriptional gene silencing and DNA
methylation in human cells (Morris et al, 2004; Castanotto et al,
2005). In our result, we found no methylation in the promoter of
E6 and E7 with pyrosequencing. It has been reported that the
frequency of promoter methylation is probably not always
consistent with the inactivation of the promoter and the expression
of downstream genes (Castanotto et al, 2005), and the representa-
tion of epigenetics inducted by siRNA is various (Morris et al,
2004; Castanotto et al, 2005). Transcriptional gene silencing in
human cancer cells could only be accompanied by histone
modification, with absence of DNA methylation (Ting et al,
2005). Thus, our findings suggest that promoter DNA methylation
may not be a kind of mechanism of transcriptional gene silencing
of HPV16 E6/E7 induced by siRNA.
In our study, the decreases in E6/E7 mRNA and protein
expression were more than 40 and 30%, respectively. The reduction
was similar to the results reported by Castanotto et al (2005).
Figure 3 The cellular growth aspect of SiHa cells treated by promoter–siRNA. (A) SiHa before transfection (0h). (B) SiHa treated with promoter-
targeting siRNA (48h), the dark arrows point to cells with vacuoles. (C) Negative control: SiHa treated with scrambled siRNA (48h). (D) Blank control:
SiHa treated without siRNA (48h). The promoter-targeting siRNA-treated cells (B) showed slower growth, with some small vacuoles in the cytoplasm of
cells.
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Figure 4 Cellular proliferation in SiHa cells treated by promoter–siRNA.
Proliferation rates of SiHa cells treated by siRNA. The x-axes show
different experiment groups and y-axes show cell proliferation rates, which
were normalised to that of the negative control.
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is probably of siRNA synthesised in vitro and transfected
by liposome in the study. Most of the siRNA transfected into
cells remains in the cytoplasm and only a small part enters the
nucleus; however, the activity of siRNA to the promoter is takes
place in the nucleus. Alternatively, siRNA might only gain access
to genomic DNA when the nuclear membrane disappears during
cell division.
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Figure 5 Cellular apoptosis and senescence in SiHa cells treated by promoter–siRNA. (A). Apoptosis of SiHa cells treated by siRNA. In the flow
cytometry chart, the x-axes represent the fluorescence intention of annexin-V–FITC, and y-axes show the fluorescence intensity of propidium iodide and
the dot in the quadrant represents the cell number. The right down quadrant shows apoptosis data. (B) Senescence of SiHa cells treated by siRNA (200 ).
Cells that showed intense green staining reflected high levels of SAb-gal activity. Further green staining appeared in cells treated with promoter-targeting
siRNA. The colour version of this figure is available online.
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Figure 6 Detection of DNA methylation and H3K9 methylation of the HPV 16 E6/E7 promoter in SiHa cells treated by siRNA. (A) Sequence of
pyrosequencing of the E6/E7 promoter. Genomic DNA was treated with sodium bisulphite to transfer unmethylated C to T, and to maintain methylated C
as C. Therefore, in the results of pyrosequencing, T represents unmethylated C. Five CpGs in the promoter region were all unmethylated. (B) H3K9me3
expression detected by ChIP and real-time PCR. DDC(t) were 0.86±0.13, 0.23±0.06 and 0.48±0.04 separately in the promoter–siRNA, negative control
and blank control. The x-axes show different experiment groups, and y-axes show H3K9me3 expression, which was normalised to that of the negative
control.
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simultaneously knocks down both extraneous viral genes
HPV 16 E6 and E7 at the transcriptional level, and consequently
inhibits proliferation and induces death in HPV 16-infected
cells. This transcriptional repression is probably induced by
histone modification rather than by an alteration of DNA
methylation.
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